Video

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer

ESMO 2025: Latest developments in endometrial cancer

ESMO 2025: Precision medicine in bladder cancer

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC

ESMO 2025: Highlights and analysis

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Best practice in precision medicine for prostate cancer

ESMO 2025: Latest in EGFR mutant NSCLC

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Neoadjuvant TAR-200 plus cetrelimab improves PCR in muscle-invasive bladder cancer

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer